Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBO Says Comparative Effectiveness Research Won’t Save Money Soon

This article was originally published in The Gray Sheet

Executive Summary

The Congressional Budget Office reiterated its stance Dec. 18 that government funding for comparative effectiveness research will be slow to yield significant savings and, for the first 10 years, will only increase the federal deficit

You may also be interested in...



Comparative Effectiveness Research Gets $1.1 Bil.; How Will Data Be Used?

The massive economic stimulus package expected to be signed by President Obama Feb. 16 includes $1.1 billion to promote comparative effectiveness research, but is vague as to what exactly should be studied and how the results should be used

Comparative Effectiveness Research Gets $1.1 Bil.; How Will Data Be Used?

The massive economic stimulus package expected to be signed by President Obama Feb. 16 includes $1.1 billion to promote comparative effectiveness research, but is vague as to what exactly should be studied and how the results should be used

Stakeholders Warn Comparative Effectiveness Research Is No Magic Bullet

As Congress moves closer to approving significant funding for comparative effectiveness programs, questions remain over how to structure a sustainable system for conducting the research and how to avoid unintended consequences in sharing the data

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel